Assessing the Economic Impact of Cancer Care: A Study on Out‐of‐Pocket Expenditures and Utilization in South Korea
Do Hee Kim, Yejin Kim, Jun Su Park, Sang Gyu Lee, Hyuk‐Jae Chang, Tae Hyun Kim

TL;DR
This study examines the financial burden of cancer care in South Korea, finding that cancer patients still face high out-of-pocket expenses despite government policies.
Contribution
The study quantifies incremental healthcare utilization and out-of-pocket expenditures specifically for cancer patients in South Korea.
Findings
Cancer patients had 0.39 more hospitalizations and $482.8 in additional annual out-of-pocket expenses compared to non-cancer patients.
Inpatient services accounted for $340.2 of the out-of-pocket expenses for cancer patients.
Healthcare utilization and expenditures varied significantly across different cancer types.
Abstract
Cancer remains one of the leading causes of mortality and financial distress worldwide. In South Korea, the government introduced a benefit extension system in 2013 aimed at mitigating the financial strain associated with cancer treatment. However, cancer patients continue to bear significant out‐of‐pocket (OOP) expenses. This study aims to quantify the incremental healthcare utilization and OOP expenditures incurred by cancer patients in South Korea. Utilizing data from the 2019 Korean Health Panel (KHP), we assessed cancer‐related healthcare utilization and OOP expenditures. A generalized linear regression model, adjusted for demographic and socioeconomic variables, was employed. Healthcare utilization was measured by hospital admissions, outpatient visits, and emergency room (ER) visits, while OOP expenditures encompassed services including both covered and not covered by the…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsEconomic and Financial Impacts of Cancer · Health Systems, Economic Evaluations, Quality of Life · Pharmaceutical Economics and Policy
